GHIT 3.0 Strategic Plan
FY2023-FY2027
VISION

Our vision is a world free of neglected infectious diseases that affect over a billion people with the aim of achieving health equity.

MISSION

We leverage Japanese innovation and leadership to fight against neglected infectious diseases through investing in research and development and promoting global partnerships.
Celebrating 10 Years Since Our Founding

In 2023, the Global Health Innovative Technology Fund (GHIT Fund) celebrates its 10th anniversary. We are grateful to our funding partners and sponsors for their support and collaboration over the past decade, to our product development partners for their passion and tireless efforts in the fight against neglected infectious diseases, and to the global health community for its solidarity and partnership.

The concept of the GHIT Fund was born from notes written on a paper napkin by the late Dr. Tachi Yamada and GHIT’s founding CEO, Dr. BT Slingsby, in 2013. Since then, we have been fighting neglected diseases in low and middle-income countries by connecting ideas, people, and innovations from around the world. In our experience, passion and vision are more powerful tools than most may realize. Each new drug in development or nearing approval has the potential to save tens of millions of lives.

Cumulative investments over the past 10 years have totaled approximately 30 billion yen, supporting more than 100 R&D projects. More than 50 projects are currently underway, of which 12 are in clinical development. As of April 1, 2023, GHIT’s family of active Japanese and global partners is 170-strong, all supporting our mission to connect Japanese pharmaceutical companies and universities with global partner institutions to accelerate global health innovation.

GHIT 3.0 Strategic Plan

In our third phase of operations (FY2023 – FY2027), we will continue to promote the development of therapeutics, vaccines and diagnostics through global collaboration, aiming for greater efficiency and acceleration of R&D than ever before. Our third five-year plan, “GHIT 3.0”, features three strategic pillars: Galvanize Innovation, Catalyze Partnerships and Maximize Impact. The work under these pillars reinforces our role as an international organization that promotes innovation and product development for neglected diseases prevalent mainly in low and middle-income countries.

Developing new medicines is no easy task, requiring an average of over ten years of painstaking effort and tens of billions of yen to develop a single medicine. But the time and investment are worth it. GHIT’s projects, which have been created and nurtured over the past decade, are about to bear fruit. By delivering the therapeutics, vaccines and diagnostics that result from our development partnerships to sick patients as quickly as possible, we will save countless lives and prevent untold suffering and stigma from the complications of neglected diseases.

At the GHIT Fund, we will continue to promote innovation and R&D from Japan and fight neglected infectious diseases through global partnerships. We remain steadfast in our mission to reduce the suffering caused by neglected infectious diseases that affect more than a billion people, in support of a healthy world for all. We leap into this work together with you, as partners.

We look forward to your continued support and cooperation.
Value of the GHIT Fund

Japanese Innovation
Improving global health by identifying and investing in Japanese innovation

Global Partnership
Facilitating cross-border & cross-sector partnership to accelerate product development

Support Globalization
Advancing the Globalization of Japan’s pharmaceutical industry and reinforcing ESG management

GHIT Product Development Partners

Japanese Organizations 59  Non-Japanese Organizations 111

As of April 1, 2023

＝ Clinical Candidates and GHIT Partners
Malaria is caused by a parasite called *Plasmodium* and is transmitted to humans through the bite of a female *Anopheles* mosquito carrying this parasite. There are five types of parasites which cause malaria in humans, and among these, the *Plasmodium falciparum* and the *Plasmodium vivax* have become a threat.

247 million | 619,000
---|---
Infected in 2021 | Deaths in 2021

Tuberculosis (TB) is one of the 10 leading causes of death globally. It is caused by bacteria (*Mycobacterium tuberculosis*), which most often show symptoms in the lungs, and spread through airborne transmission. TB is the leading cause of death among HIV-positive people. Multidrug-resistant TB (MDR-TB) also remains a public health crisis and a threat to health security.

10.6 million | 1.6 million
---|---
Infected in 2021 | Deaths in 2021

Neglected Tropical Diseases (NTDs) – a group of 20 communicable diseases prevalent in tropical and subtropical conditions in approximately 150 countries – affect more than one billion people and cost developing economies billions of dollars every year. Populations living in poverty, without adequate sanitation, and in close contact with infectious vectors, domestic animals, and livestock are those worst affected.

1.6 billion
Infected in 2021

GHIT Fund has played the pivotal role in promoting research and development to fight neglected diseases by making most of Japanese technology and innovation and promoting global partnership between academia, public and private sector.

Peter Piot, MD, PhD
Professor of Global Health, London School of Hygiene & Tropical Medicine
Special Advisor on COVID-19 to the President of the European Commission

We reached yet another significant milestone for the Consortium with the announcement that the European Medicines Agency had validated for review our application for our potential new pediatric treatment option for schistosomiasis. Having reached this milestone after more than 10 years of intense and collaborative work makes me very proud.

Dr. Jutta Reinhard-Rupp
Chair of the Pediatric Praziquantel Consortium
Board Head of the Global Health Institute at Merck

GHIT’s achievements are not limited to promoting research and development, but also include contributing to the globalization and human resource development of researchers in the field of infectious diseases in Japan. I believe that GHIT’s unique investment in joint research between Japanese and foreign organizations further strengthens the research capabilities and partnerships of Japanese research institutions.

Prof. Kiyoshi Kita
Dean, Graduate School of Tropical Medicine and Global Health, Nagasaki University

As of March 31, 2023

GHIT Fund
**GHIT 3.0 Strategic Plan**

**Galvanize Innovation**

### Accelerate Late-Stage Product Development

**Strategic Plan FY2023-FY2027**

<table>
<thead>
<tr>
<th>Objective</th>
<th>R&amp;D milestone</th>
<th>Targeted by March 2027</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leverage innovations from Japanese biopharma and academia</td>
<td>Lead Identification</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Preclinical</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Phase I</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Phase II - Phase III</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Registration</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Promote Open, Collaborative R&D

* Co-creation of products through international joint research and transparency in sharing findings between various industries of academia, research institutes, pharmaceutical companies, SMEs and Japanese and international startups.

---

[GHIT Fund Logo]
GHIT 3.0 Strategic Plan
Maximize Impact

Leverage Resources
- Continue to leverage limited resources by exploring various funding mechanisms and prioritizing sustainability.

Enhance Governance and Institutional Management
- Further enhance corporate governance and institutional development.
- Ensure organizational sustainability through deployment of appropriate HR management and financial strategies.

Optimize Portfolio

GHIT 1.0
FY2013-FY2017
Phase I: Creation
- Establish an innovative funding mechanism to create international public goods from Japan through public-private partnership (Japanese government × private companies × foundations).
- Launch R&D projects utilizing Japanese drug discovery technologies and innovations.

GHIT 2.0
FY2018-FY2022
Phase II: Growth
- Advance product development pipelines through active management of existing portfolio alongside proactive new investments in innovative technologies applicable to global health.
- Support access and delivery through close collaboration with international organizations.

GHIT 3.0
FY2023-FY2027
Phase III: Harvest
- Accelerate product development for malaria, tuberculosis and NTDs.
- Optimize portfolio and resources to maximize the investment impact and further strengthen institutional development.
- Foster and promote domestic and international partnerships aimed at sparking innovation.

2023.5
GHIT 3.0 Strategic Plan
Catalyze Partnerships

Create an Enabling Environment for Access & Delivery

GHIT works proactively with product development partners to help them develop robust launch strategies and establish strategic, product-focused partnerships for appropriate, timely access and delivery of their innovations. Key considerations are illustrated below.

Access & Delivery

Regulatory
Financing
Manufacturing
Procurement & Supply Chain
Policy & Advocacy

Regulatory Harmonization, Capacity Building (UNDP-led Access and Delivery Partnership (ADP))

GHIT facilitates strategic partnerships for Access and Delivery

Top-down approach:
Create a platform for aligned action across the innovation–access–delivery continuum.

Bottom-up approach:
Ensure launch strategies for GHIT-invested clinical candidates

Strengthen Strategic Partnerships, Focusing on LICs & LMICs

* Continue to extend institutional presence in LICs and LMICs and explore innovations from the ground up.

Demonstrate End-to-End R&D/A&D Ecosystems

* Leverage UNDP and other global networks to ensure seamless connectivity between innovation (R&D) and access and delivery (A&D).
Leadership

Council

Composed of representatives of the Japanese government, global foundations and private companies which contribute funding, GHIT’s Council votes on important affairs, such as the election and dismissal of governors, amendments to the articles of incorporation, and the approval of financial statements.

Takeshi Akahori  
Ambassador, Director-General for Global Issues  
Ministry of Foreign Affairs

Eiji Hinoshita, MD, Ph.D, MSc.  
Assistant Minister for Global Health and Welfare  
Ministry of Health, Labour and Welfare

Trevor Mundel, MD, PhD  
President, Global Health  
Bill & Melinda Gates Foundation

Cheryl Moore  
Chief Research Programmes Officer  
Wellcome

Astellas Pharma Inc.  
Kenji Yasukawa  
Representative Director, Chairman of the Board

Chugai Pharmaceutical Co., Ltd.  
Osamu Okuda, PhD  
Representative Director, President & CEO

Daichi Sankyo Company, Limited  
Sunao Manabe, Ph.D  
Representative Director, Executive Chairman & CEO

Eisai Co., Ltd.  
Haruo Naito  
Representative Corporate Officer and CEO

Shionogi & Co., Ltd.  
Isao Teshirogi, PhD  
Chairman of the Board and Representative Director, President and CEO

Takeda Pharmaceutical Company Limited  
Christophe Weber  
Representative Director, President and CEO

Board of Directors

Composed of global health and management experts, GHIT’s Board of Directors oversees the work of the leadership team and votes on important affairs related to business management, such as the approval of important regulations, mid-term strategies, annual plans, budgets, and investment opportunities.

Chair & Representative Director  
Himki Nakatani, MD, PhD, MHPEd  
Visiting Professor  
Keio University School of Medicine

Vice Chair  
Peter Piot, MD, PhD  
Professor of Global Health, London School of Hygiene & Tropical Medicine  
Special Advisor on COVID-19 to the President of the European Commission

Executive Director  
Osamu Kunii, MD, PhD, MPH  
CEO, GHIT Fund

Mahima Datla  
Managing Director  
Biological E. Limited

Satoshi Ezoe, MD, MPH, MPA, PhD  
Director, Global Health Policy Division  
International Cooperation Bureau  
Ministry of Foreign Affairs

Tetsuya Itani  
Director  
Office of Global Health Cooperation  
Ministry of Health, Labour and Welfare

Daikichi Momma  
Vice Chairman  
Institute for International Economic Studies

Ann M. Veneman, JD  
Former Executive Director, UNICEF  
Former Secretary  
United States Department of Agriculture

Supervisory Board Member  
Hikaru Ishiguro, LLM  
Statutory Auditor  
INSPIRE Corporation

Saori Nakamura  
Attorney at Law  
Hirayama Nagareya Shirai Law Office

Supervisory Board Member  
Ko-Yung Tung, JD  
Lecturer on Law, Harvard Law School,  
Former Senior Vice President and General Counsel, World Bank

Ex-Officio  
Katey Einterz Owen, PhD  
Director, Neglected Tropical Diseases Pharmaceutical Industry Leadership Engagement  
Bill & Melinda Gates Foundation

Richard Seabrook, PhD, MBA  
Independent Senior Advisor, Innovations,  
Wellcome CEO 360Biomedical Ltd  
Royal Society Entrepreneur in Residence University of Bristol

2023.5
Leadership

Selection Committee

Composed of domestic and foreign experts with a wealth of knowledge and experience in R&D of therapeutic agents, vaccines, and diagnostic agents, the Selection Committee (SC) examines and evaluates applications and progress reports from program applicants and recommends investment opportunities to the Board of Directors. To avoid any conflict of interest between our backers and development partners, the SC does not include private sector representatives.

Co-Chair
Ann Mills-Duggan, PhD
Independent Consultant

Co-Chair
Naoto Uemura, MD, PhD
Professor, Department of Clinical Pharmacology and Therapeutics
Oita University Faculty of Medicine

Sophie Allauzen, PhD
Independent Diagnostic Expert

Ralf Clemens, MD, PhD
Independent Vaccine Expert

Ken Duncan, PhD
Deputy Director
Drug Discovery & Translational Sciences
Bill & Melinda Gates Foundation

Ken Ishii, MD, PhD
Professor, Institute of Medical Science
University of Tokyo

Timothy Jinks, PhD
Head, Infectious Diseases Interventions
Wellcome

Hiroo Koyama, PhD
Platform Unit Leader
Drug Discovery Chemistry Platform Unit
RIKEN Center for Sustainable Resource Science

Karen L. Menge
Independent Consultant

Gerd Michel, PhD
Independent Consultant

Dennis Schmatz, PhD
Former Head, Infectious Diseases Research
Merck Research Labs, USA
Former Head, Research, MSD-Japan

Anna-Karin Tidén, PhD, MRSC
Independent Medicinal Chemistry Expert

Rieko Yajima, PhD
Director, Drug Discovery Innovation
SPARK Program in Translational Research
Stanford University School of Medicine

Naoto Uemura, MD, PhD
Senior Director, Investment Strategy
Business Development

Sophie Allauzen, PhD
Independent Diagnostic Expert

Kazue Seki
Director, External Affairs & Corporate Development

Miho Takazawa, MBA
Senior Director, Finance & Operations

Leadership Team

The leadership team facilitates the development of business, investment, and organizational growth strategies, executes strategies based on the approval of the Board of Directors, and implements administrative tasks.

Osamu Kunii, MD, PhD, MPH
CEO

Kio Yamabe, MBA
COO

Kei Katsumo, MD, MPH
Senior Director, Investment Strategy
Business Development

Eriko Mugitani
Associate Director,
Brand Communications

Kazue Seki
Director, External Affairs & Corporate Development

Miho Takazawa, MBA
Senior Director, Finance & Operations

Hayato Urabe, PhD, MPIA
Senior Director, Investment Strategy
Portfolio Development & Innovations
GHIT Fund is a Japan-based global public-private partnership fund for global health R&D. We invest in nonprofit product development for malaria, tuberculosis, and Neglected Tropical Diseases (NTDs). GHIT’s sponsor companies provide in-kind services in support of GHIT’s mission.

As of April 1, 2023

Funding Partners and Sponsors

Government

- Full Partners
  - MOFA Japan
  - UNDP

Foundation

- Full Partners
  - Bill and Melinda Gates Foundation
  - Welcome

Private Companies

- Full Partners
  - Astellas
  - Chugai
  - Daiichi Sankyo
  - Eisai
  - ShionoGi
  - Takeda

- Associate Partners
  - Fujifilm
  - Otsuka

- Affiliate Partners
  - Kyowa Kirin
  - Merck
  - Mitsubishi-Tsuji Pharma

- Sponsors
  - BCW
  - Diligent
  - Forbes
  - MORI
  - Morrison Foerster
  - Salesforce
  - Zoom

As of April 1, 2023